Objective: To determine the influence of a 7-day course of postoperative antibiotherapy (cefpodoxime) on surgical site infections (SSI) after tibial plateau leveling osteotomy (TPLO). Study design: Prospective, randomized, double-blinded, placebo-controlled clinical study. Sample population: One hundred fifty client-owned dogs, with consent. Methods: Dogs undergoing arthroscopy-assisted TPLO were randomly assigned to 1 of 2 groups, the placebo group receiving perioperative cefazolin and 7 days of placebo medication after surgery or the treatment group receiving perioperative cefazolin and 7 days of postoperative cefpodoxime. Twenty-seven factors were analyzed for association with SSI by using univariate analysis, Fisher's exact test, or Wilcoxon rank-sum test. Results: SSI rates did not differ (P = .34) between the placebo group (17%; 95% confidence level [CL] 7.94%-26.43%) and the treatment group (11% SSI; 95% CL 3.98%-18.88%). The probability that > 23% of dogs would benefit from postoperative antibiotherapy was less than 5%. The only association between the factors tested in this study and SSI involved the body weight (kg), with each 1 unit increase in kilogram weight increasing the odds of developing an SSI by 4.7%. Conclusion: Although the wide CL may be consistent with a type II error, a 7-day course of cefpodoxime after arthroscopy-assisted TPLO did not influence postoperative SSI in the population tested here. In addition, only a small proportion of dogs would benefit from postoperative antibiotherapy under the conditions of our study. Clinical significance: These results should prompt surgeons to reconsider systematic antibiotherapy after TPLO and justify additional studies to determine whether dogs predisposed to infection could benefit from such an approach.
of the original surgery, 2 translating into $9.6-$15.9 million spent on TPLO SSI annually in the United States. Infections can create stress for both, as well as between, owners and veterinarians and have a financial impact on pet owners and surgeons. In addition, inappropriate use of prophylactic antibiotics is associated with emergence of resistant bacteria. [10] [11] [12] Prevention of development of resistance should be a goal of every antimicrobial therapy. 10 Stifle surgeries, especially TPLO procedures, are associated with higher rates of SSI than other clean procedures. [7] [8] [9] Factors contributing to increased SSI are multifactorial, 8, [13] [14] [15] and many surgeons prophylactically prescribe antibiotics. Scientific studies evaluating SSI in TPLO procedures have produced conflicting results, [7] [8] [9] 11, 12, [14] [15] [16] [17] [18] and many are limited by their retrospective nature. Much debate focuses on the impact of antibiotics on SSI rates in TPLO patients and individual surgeons' protocols vary widely (Table 1 ). Recent concerns regarding overuse of antibiotics by veterinarians 17 along with the development of antibiotic-resistant bacteria 10, 17 compel us to examine our reasoning for postoperative antibiotherapy to prevent perpetuating anecdotal dogma. The objective of this study was to determine the influence of a 7-day course of postoperative antibiotherapy (cefpodoxime) on SSI after TPLO and examine variables that may have contributed to SSI. Our null hypothesis was that there would be no difference between TPLO SSI rates in our placebo and treatment groups vs the 2-sided alternative hypothesis.
| MATERIALS AND METHODS
From May 15, 2015 until February 15, 2017 , all canine arthroscopy-assisted TPLO patients at a private practice referral hospital that met the inclusion criteria were enrolled (with owner consent) and randomly assigned (via coin toss performed by DS) to 1 of 2 groups (placebo or treatment group). Both groups received antibiotics perioperatively (cefazolin 22 mg/kg IV within 60 minutes of surgery start time and intraoperatively every 90 minutes). Antibiotics were recommended to be given 30-60 minutes before beginning surgery in a study on pharmacokinetics on cefazolin. 18 Thereafter, the placebo group received an oral placebo every 24 hours for 7 days, and the treatment group received oral antibiotics for 7 days (cefpodoxime at 5-10 mg/kg orally every 24 hours). Dog weights were grouped for ease of cefpodoxime dosing, with each dog receiving the closest onehalf tablet equivalent to a dose of 5-10 mg/kg. Placebo medication was made specifically for this study by a compounding pharmacy (The Medicine Shoppe, North Canton, Ohio).
All dogs were diagnosed with CCLR clinically (positive tibial thrust or cranial drawer), admitted for single session stifle arthroscopy TPLO, free of major health problems, with American Society of Anesthesiologists scores of 1 or 2.
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All sizes of dogs (including small dogs) for which appropriate doses could be administered with cefpodoxime half tablets were included. Dogs were excluded if they had had previous ipsilateral stifle surgery, if they had moderate or severe dermatitis near the expected surgical site or epidural site, or if the dogs had been prescribed antibiotics within 30 days prior to the TPLO. Any dog enrolled in the study for their first CCLR that acquired an SSI during the study period was excluded from the study for the contralateral CCLR repair. Any dog that did not follow study protocol was excluded, and the reason was noted (Table 2) .
Data recorded from medical records are listed in Tables 3 and 4 . Arthroscopy camera, light cable, and arthroscope sterilization method (ethylene oxide [ETO] sterilization vs glutaraldehyde [12-minute submersion followed by sterile saline rinse]) were recorded. The TPLO saw was sterilized by ETO or was sterilely sleeved (Steri Drape; 3M Health Care, St Paul, Minnesota) via a previously described standardized method. 23 Pet owners, surgeons, residents, interns, and technicians were blinded to placebo vs treatment group. At admission, a clinical study coordinator recorded dog name and identification number on a confidential list bearing the predetermined randomly assigned (via coin toss) lines by group (placebo vs treatment group). Investigators recorded all data on a personalized data sheet without knowing whether the dog was receiving cefpodoxime or placebo. Doctors calculated doses of 5-10 mg/kg for each dog. The clinical study coordinator then provided a prescription of precounted vials (7 tablets; 1 tablet to be given once daily for 7 days) of the appropriate cefpodoxime tablet strength or similarly sized placebo. The vials were precounted and sent home with a standard prescription label that included placebo or cefpodoxime with the appropriate tablet strength and directions. Oral medication was started in the hospital postoperatively 6 hours after the last dose of cefazolin. The dog group list was kept confidential until 8 weeks after the study enrollment closing. The placebo was created in white-on-white gel caps, and, to ensure the integrity of our blinding, cefpodoxime tablets were inserted into a white-on-white gel cap for disguise.
| Dog preparation
All dogs received similar premedication (midazolam 0.25 mg/kg, acepromazine 0.01-0.05 mg/kg, or dexmedetomidine 0.005-0.008 mg/kg and hydromorphone 0.1 mg/kg IM or IV) and induction (diazepam 0.25 mg/kg IV, propofol 3-4 mg/kg IV) and were maintained on 1%-2% isoflurane. Each dog received a preservative-free morphine and bupivacaine epidural of 0.1 mg/kg and 0.55 mg/kg, respectively, for analgesia immediately after induction. A dirty scrub (exam gloves, 2% chlorhexidine solution) was performed after clipping, followed by a clean scrub of the hanging limb (exam gloves, sterile gauze, and 4% chlorhexidine scrub for > 5 minutes) after the dog was positioned in the operating room. Quarter drapes and an over-drape that incorporated the surgical instrument table were used. The distal limb was wrapped with sterile drape material followed by sterile roll gauze. Application of a self-adhesive drape (Ioban; 3M Health Care) covered the entire exposed limb and limb wrap, providing a completely water-impervious barrier. Timers were used in the operating rooms to ensure antibiotics were punctual.
| Surgeon preparation
Surgeons performed hand wash with nail pick to remove gross debris prior to the first surgery of the day. Prior to each surgery, the surgeons prepared hands and forearms with a commercial hand rub (Sterillium; Medline Industries, Mundelein, Illinois) per manufacturer's recommendations (2-minute contact time). Surgeons wore orthopedic gloves (Encore orthopedic latex gloves; Ansell Medical GBU, Iselin, New Jersey) in addition to surgical gown, cap, and mask.
| Surgery
All procedures were performed by an American College of Veterinary Surgeons diplomate surgeon (RMD; primary surgeon) with 1 of 2 residents or 3 trained surgical interns performing varying portions of the procedure under direct supervision. Stifle arthroscopy was performed prior to TPLO to assess, debride damaged CCL and menisci, and evaluate overall joint health. Dogs with meniscal tears and minimal to no competent CCL fibers had the remaining CCL removed by combined powered shaving radiofrequency ablation (Electroblade Resector; Smith-Nephew, Andover, Massachusetts) and a caudal meniscotibial ligament release performed by using radiofrequency ablation. All TPLO plates used were locking plates produced by the same manufacturer (New Generation Devices, Glen Rock, New Jersey BP, blood pressure; IVC, IV catheter; Postop, postoperative; Preop, preoperative; TPLO, tibial plateau leveling osteotomy. All factors with P < .2 were included in the multivariate logistic equation.
pin hole was not closed at the preference of the primary surgeon.
| Postoperative care
Dogs received 0.1 mg/kg hydromorphone IV at extubation if assessed painful despite epidural. Within 10 hours of surgery, dogs were transitioned to oral tramadol (3-5 mg/kg orally once every 8-12 hours) and an oral nonsteroidal antiinflammatory drug (NSAID). All dogs were sent home with tramadol and an NSAID at the above doses for 7 and 10 days, respectively. Dogs with anxiety were prescribed 3-5 mg/kg of trazodone orally every 8 hours while hospitalized and during recovery at home as required. Injectable antianxiety medications were provided in hospital as required and included acepromazine and/or dexmedetomidine. A modified Robert-Jones bandage placed immediately postoperatively was removed the morning after surgery. Dogs were released from the hospital the day after surgery. Indwelling IV catheter time (hours) was recorded along with any injectable rescue antianxiety medications that were given overnight. Dogs were followed for a minimum of 8 weeks, with rechecks at 2 weeks and 8 weeks postoperatively, the latter including radiographs. If owners believed that restricting their pet's activity would be difficult, trazodone was offered for up to 8 weeks at the same in-hospital dose. Elizabethan collars (E-collar) were placed on dogs while in the hospital when dogs showed a tendency to lick; these dogs were sent home with a custom-fit E-collar. Letters were faxed to referring veterinarians at both the 2 and 8 week recheck appointments reminding them of the dogs' enrollment in the antibiotic study and requesting any novel medical records. At the 2-week reevaluation, owners were asked if they had administered and finished the medication as prescribed. Data collected at both reevaluations included lameness score by primary surgeon, resident, or trained surgical intern (0-5 scale); description of palpation (range of motion, clicking, popping, crepitus, or pain); description of incision (redness, swelling, pain, warmth, discharge); and description of stifle effusion (none, mild, moderate, severe). Interpretation of radiographs at 8 weeks included description of osteotomy site (healed yes/no) as well as patellar tendon appearance (normal vs desmitis), implants (in place yes/no, intact yes/no), and stifle effusion (yes/no). Desmitis was differentiated from patellar tendon thickening by the presence of stifle effusion. All parties continued to be blinded until after the end of the study period.
| Definitions
Surgical site infection has been defined in multiple ways in veterinary medical studies. [7] [8] [9] 11, 14, 17 In this study, SSI were divided into superficial, deep, and intra-articular and characterized as closely as possible to previously published descriptions (modified from Mangrum et al). 24 Superficial infections were those demonstrating purulent discharge from the superficial incision, with or without laboratory confirmation, or which demonstrated 3 or more of the following if no drainage was present: redness, pain, swelling, or heat at the incision. Deep SSI were characterized by purulent discharge from deep tissues, but not the joint, or if the surgical wound dehisced full thickness >2 cm length. Mild superficial dehiscence (<2 cm of incision) without the presence of other clinical signs of infection was not considered to be SSI because these lesions healed on their own or with minimal medical intervention and no antibiotics. These complications were considered to be minor and were cleaned and closed with staples (if appropriate). When there were signs of infection or drainage, the wound was treated as previously described with a bacterial culture and antibiotics. Joint SSI were defined as infections that involved the stifle joint fluid in which the joint fluid was collected aseptically and revealed bacteria according to microscopic analysis and/or positive bacterial culture. Complications were divided into major and minor; major complications required additional surgery; whereas minor complications did not. 25 
| Statistical analysis
Data were divided into 2 groups (placebo and treatment groups), and occurrence of SSI (yes/no) was documented. Twenty-seven factors were analyzed for association with SSI (Table 4 ) by using univariate analysis. Binary and categorical factors were analyzed by means of χ 2 . When a sample was too small for χ 2 , a Fisher's exact test was performed. Assessment of normality was by histogram and normal probability plot. Not all data were normally distributed; therefore, a Wilcoxon rank-sum test was performed instead of an unpaired t test; all ordinal and continuous data were analyzed by means of Wilcoxon rank-sum test. For dogs with both stifles included in the study, each stifle was treated as an independent stifle to increase the power of the study because these stifles made up 21% of the total number of stifles in the study. We acknowledge that there may be some factors between stifles of the same dog that are not different. Multivariate analysis was then performed that included any factor with a univariate P < .20 (body weight in kilograms, sterilization method of TPLO saw, time IV catheter was in place). 26 Factors were retained in the equation if P < .20.
All previous nonincluded and deleted factors were then added to the equation 1 at a time and were retained if P < .20. All factors had variance inflation factor <2.5 (acceptable). Odds ratios were then calculated for the 2 factors that were significant in the multivariate logistic regression. The relationship between body condition score (BCS) and the logOdds SSI was linear by means of the BoxTidwell transformation 27 as was body weight (BW) in kilograms and logOdds SSI. Binomial distribution overlap was calculated (with 64 trials from each distribution) to determine the benefit of treatment probability by using an online calculator (http://www.di-mgmt.com.au/binomialcalculator.html). All other statistics were performed in a commercially available software program (SAS 9.3; SAS Institute, Cary, North Carolina).
| RESULTS
One hundred fifty stifles met inclusion criteria. Sixteen stifles were censored from the study (see Table 2 ). Fourteen dogs had both stifles included in the study. Therefore, 134 stifles and 120 dogs were included with a minimum of 8 weeks follow-up, with 64 stifles in the placebo group and 70 stifles in the treatment group. Data points collected preoperatively, intraoperatively, and postoperatively are presented in Table 4 . Breed distribution included 49 mixed, 31 Labradors, 16 golden retrievers, 4 each of boxers, pit bulls, mastiffs, and German shepherds, and single dogs of various other breeds. Among the 120 dogs, 67 (56%) were spayed females, 4 (3%) were intact females, 3 (2%) were intact males, and 46 (38%) were neutered males. Seventyseven of the TPLO were performed on the left stifle, and 57/ 134 TPLO were performed on the right stifle. Mean time to follow-up was 12.5 months (range: 2.0-19.6) for all dogs included in the study. During the study period (time from the first dog enrollment to 8 weeks after last study dog enrollment), the incidence of SSI for the placebo group was 17% (11/64; 95% confidence limit [CL] 8.0%-26.4%). This was not statistically different from the treatment group incidence of 11% (8/70; 95% CL 4.0%-18.8%; P = .34). The mean time from surgery to SSI diagnosis was 16.1 days (range, 7-28) in the placebo group and 13.7 days (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in the treatment group. There was no significant difference between mean time from surgery to SSI diagnosis between placebo and treatment groups.
Major complication rate was 1 of 134 (0.7%), and minor complication rate was 23 of 134 (17.2%). There was no statistical difference between complication rates comparing placebo and treatment groups. One dog had a major complication. At the 2-week reevaluation, the dog was doing very well. While walking to the car after the reevaluation, the dog escaped from the owner and fell backward when attempting to leap into the car, fracturing its tibial tuberosity and fibula, mildly destabilizing the rotated tibial plateau. This injury required surgical therapy with pins, tension band, and a short-term external skeletal fixator. Final evaluation revealed normal use of the surgically treated limb. The 19 dogs with SSI had minor complications, and 4 additional dogs had minor incisional dehiscence, suspected from licking; these were cleaned with 2% chlorhexidine solution, and an E-collar was prescribed with no antibiotics. Occasionally, staples were used to appose the 1-2 cm of dehisced wound; however, this was performed while dogs were awake, so it was not considered surgical. None of these dogs developed SSI. No dogs had major adverse effects from either the placebo medication or the cefpodoxime.
The most common bacterial isolate was Staphylococcus aureus; Table 5 lists additional bacterial species cultured. Four of 18 infections were methicillin resistant, including all 3 S pseudointermedius and the only S schleiferis cultured. None of the S aureus were methicillin resistant. Eight dogs had > 1 bacterial species revealed by culture. Only 1 dog that had a culture performed had no bacteria cultured; however, the incision was still considered infected based on our definition and received 14 days of cephalexin. All infections resolved with antibiotic administration. No TPLO plates were removed during the study period. All SSI were superficial.
Twenty-seven variables were compared between placebo and treatment groups to ensure similarity (the same variables listed in Table 4 ). There were no statistical differences between the placebo and treatment groups with regard to these variables except whether the dogs had previously had contralateral CCL repair, which was significantly different (P = .03); more dogs (n = 19) with previous contralateral CCLR repairs were included in the treatment group compared with the placebo group (n = 10). This has the potential to affect our results as a selection bias. Dogs with and without SSI were compared by using 27 variables that were analyzed with univariate analysis (Table 4) , and all factors with P < .20 were retained in the multivariate logistic equation. Multivariate analysis yielded a significant association between BW and SSI (P = .03). Additional variables included in the multivariate logistic equation are listed in Table 6 along with their odds ratios. There was no statistical correlation between SSI and duration of anesthesia, duration of TPLO surgery, or any other of the 27 variables listed in Table 3 . Group (placebo vs treatment) had no effect on SSI. The method of sterilization of the TPLO saw was not statistically different between the placebo and treatment groups; however, it approached significance with P = .071. Binomial distribution calculations in this study provide evidence that there is <5% probability that > 23% of canine patients will benefit from postoperative antibiotics.
The number needed to treat (NNT) was also calculated. The NNT was 16.7 dogs, which means that almost 17 dogs would have to be treated with cefpodoxime to prevent 1 adverse outcome of SSI.
| DISCUSSION
SSI rates after TPLO did not differ between dogs treated with a placebo and cefpodoxime postoperatively in this study. Binomial distribution calculations provide evidence that there is <5% probability that > 23% of canine patients will benefit from postoperative antibiotherapy. This finding implies that postoperative antibiotics would be prescribed to many dogs that will not develop SSI, whereas only a small proportion of dogs would benefit from such treatment. Combined, these results should prompt surgeons to reflect on their practice with regard to antibiotherapy after TPLO.
In our referral practice, we perform approximately 10 TPLO per week. When we take into consideration our NNT of 16.7 dogs, this means that, in 1 month, our hospital would have to treat 40 dogs with cefpodoxime to prevent approximately 2 SSI; therefore, about 38 dogs would have received cefpodoxime when it may not have been required. Some surgeons may find this acceptable, especially because cefpodoxime has minimal side effects; however, it is ultimately up to each surgeon to determine his/her standard of practice: preventing SSI and managing potential side effects of the antibiotics in 38 dogs or managing SSI in 2 dogs and avoiding the potential side effects in the rest.
The present study also found that each increase of 1 kg of BW increased the odds of getting an SSI by 4.7% (Figure 1) . A dog weighing 30 kg is therefore 58% more likely to develop a SSI than a dog weighing 20 kg, and a dog weighing 50 kg is 628% more likely to develop an SSI than a dog weighing 10 kg. This predisposition could reflect the relative ease of controlling smaller dogs, which could influence owner compliance regarding activity restriction. Smaller dogs may also be more likely to be routinely groomed and bathed, potentially decreasing their cutaneous bacterial load, which is where the majority of pathogens in the present study originated from. Increased SSI rate in heavier dogs could also be related to obesity and the subsequent chronic inflammatory state, although BCS was not detected as a predictor of SSI in this study. Pharmacokinetics and distribution of cefazolin in obese dogs require additional studies to determine their potential role in the increased SSI rate of these dogs.
We were unable to determine whether antibiotherapy had an effect in our population of heavier BW dogs because of the low number of infected cases. However, the correlation between BW and SSI is consistent with other studies. 4, 28 The SSI rate after TPLO in 208 dogs over 50 kg has been reported to reach 21.3%, with diagnosis of SSI in 24 of 40 (60%) dogs within 15 days and diagnosis of SSI in 6 of 40 (40%) dogs at least 2 weeks postoperatively. 20 In a retrospective study of 476 TPLO, the SSI rate was 14 of 467 (2.9%), with all 14 infections detected within 1 year postoperatively and the majority (11/14) detected within 6 weeks. 9 These reports support the concept that most infections occur soon after surgery. In the present study, the mean follow-up time was 13.1 months (range, 2.0-22.1), decreasing the risk of missing infections. However, we cannot rule out the potential for late SSI, especially those associated found that the administration of cephalexin for 14 days protected against SSI after TPLO. This discrepancy between studies may be explained by differences in antibiotic selection, duration of treatment, and the retrospective nature of the study by Fitzpatrick and colleagues. One advantage of the present study is its prospective nature and the active evaluation for infection (including routine follow-up with referring veterinarians and requesting novel medical records) compared with retrospective studies, in which the infection rate may be falsely low. The prospective nature of the present study may have contributed to the study's 17% placebo and 11% treatment group SSI rates because it is unlikely that we missed any early SSI as a result of our proactive questioning of clients and referral veterinarians regarding SSI and requesting novel medical records after each visit. The duration of antibiotherapy in our study took into consideration the current recommendation from the National Surgical Infection Prevention Project for human orthopedic surgery to discontinue all antimicrobial therapy by 24 hours after surgery 10 as well as the range of duration in previous studies (Table 1) . Seven days of cefpodoxime was deemed a logical choice by the authors to compare to a placebo regimen because of its good spectrum for skin pathogens while maximizing owner compliance with once daily dosing. The most common bacterial isolates in our study were Staphylococcus spp. A third-generation cephalosporin, such as the cefpodoxime, may therefore be inferior to a first-generation cephalosporin, such as cephalexin, for prophylactic antibiotherapy after TPLO. Cefpodoxime has been used in another study of antibiotic use in dogs undergoing TPLO. 16 This antibiotic was chosen for its good coverage of expected skin pathogens and its once daily administration, which we expected would increase owner compliance over antibiotics requiring twice or 3-times daily dosing. Recent recommendations on antibiotic dose and frequency 12 suggest that previous studies may no longer be relevant. For example, cephalexin is a time-dependent antibiotic that should be given every 8 hours to ensure the antibiotic concentration is above the minimum inhibitory concentration for as long possible; 10 however, in reports of studies using cephalexin, it was prescribed only twice daily, or frequency was not specified. The present study was developed to provide a prospective, double-blinded, placebo-controlled evaluation of an antibiotic after TPLO surgery. For ease of comparison, future antibiotic studies should strive, as we did, to disclose type, route, and frequency of antibiotic dosage. Pratesi et al 28 published a prospective randomized study of 100 consecutive clean orthopedic cases and found an association between total anesthesia time and SSI; however, the present study found no such correlation, nor did Fitzpatrick and Solano 7 in their retrospective study of 1000 consecutive TPLO cases. There was no association between SSI and factors in Table 4 beside those previously discussed. Solano et al 20 found that nonlocking plates were associated with an increased SSI rate. To avoid this variable, all plates used in the present study were locking. Surgeon experience has been shown to be a risk factor for complications. 19 Our prospective study controlled for experience by including only 1 primary surgeon performing TPLO, and there was no difference between the placebo and treatment groups regarding resident or surgical intern involved in the surgery. We also found no correlation between SSI and the resident or surgical intern assisting with the case. These findings suggest that surgeon experience may have less influence on postoperative SSI when it comes to complications. Among the 120 dogs (134 stifles) in the current study, 4 had minor superficial dehiscence <2 cm that healed without antibiotics, suggesting that we should reexamine how surgeons diagnose SSI. Other authors might have included these dogs in the SSI group and prescribed antibiotics, but we do not believe that these cases should have been included as SSI; however, there is no classification system that accurately describes wound dehiscence without infection.
One limitation of this study is the wide CL, which was influenced by the low number of dogs enrolled and could generate a type II error. Another limitation is the short follow-up. Surgical site infections have been documented to occur up to 1 year postoperatively, yet we chose a minimum follow-up of 8 weeks (mean time to follow-up was 13.1 months). This time frame was chosen to facilitate data collection considering that the majority of SSI occur within 6 weeks of surgery. 9, 18 Another limitation of this study is that all surgeries were performed by a single surgeon at a single institution, limiting the extrapolation of our findings to other populations. This design was selected to minimize variables and potential differences between the study groups.
Our definitions of SSI could have influenced our SSI FIGURE 1 Graph of body weight in kilograms vs odds ratio of developing a surgical site infection in our study population incidence. In addition, although they were trained, different observers (surgeon, surgical residents, and surgical interns) were used to assess the dogs at 2 and 8 weeks postoperatively, which may have led to bias resulting from experience. Although previous studies have prospectively evaluated antibiotic administration in clean orthopedic procedures, 12, 28 this is the first published study that prospectively compares a placebo and an antibiotic in a double-blinded, randomized clinical trial of clean orthopedic procedures, or specifically TPLO. Placebo-controlled studies hold higher value compared to active control-group studies by reducing bias associated with reporting of side effects because both groups are being given a medication, ensuring that both groups are equally minimally interacted with at home. If only 1 group receives medication, there is more potential for owner neglect of the other group during the postoperative period.
In conclusion, this study did not detect a statistical difference between the placebo and treatment group SSI rates in this population of dogs. Body weight was found to increase the chance of SSI by 4.7% for each 1-kg increase in mean body weight. Binomial distributions provided evidence to support that most dogs may not clinically benefit from postoperative antibiotic usage. It is important to be mindful when prescribing antibiotics to prevent multidrug resistance. Large scale prospective studies are required to clarify whether all TPLO dogs should be prescribed postoperative antibiotics.
